FB Vision and Bausch+Lomb enter into multi-country commercial agreement to commercialize Ozodrop™ Eye Drops

FB Vision and Bausch+Lomb enter into multi-country commercial agreement to commercialize Ozodrop™ Eye Drops

(PRESS RELEASE) SAN BENEDETTO DEL TRONTO, Italy, 15-Mar-2021 — /EuropaWire/ — FB Vision, an Italian joint stock company specialized in ophthalmics, announced a partnership with Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., to commercialize Ozodrop™ Eye Drops under the brand Desodrop™, an innovative medical device based on LipozonEye® technology. The product is indicated for lubrication and corneal protection and can also be used as a soothing product for symptoms related to inflammation, also of infectious origin.

Under the terms of a multi country Private Label Agreement, an affiliate of Bausch Health will acquire the rights to market Desodrop™ Eye Drops in 16 countries in Europe.

“We are delighted that Bausch + Lomb has selected FB Vision as a strong partner to help meet the challenging and evolving medical needs associated with eye infections,” said Paolo Lategano, Chief Executive Officer FBV: “We look forward to a long-term collaboration that will be beneficial to patients”.

Media contact:

Marco Marchetti
Executive Senior VP
FB Vision
mmarchetti@fb-vision.it

Logos:

FB Vision logo

Bausch Health Companies Inc. logo

SOURCE: FB Vision